Literature DB >> 16003176

Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population.

Jin Yang1, Kei Kamide, Yoshihiro Kokubo, Shin Takiuchi, Chihiro Tanaka, Mariko Banno, Yoshikazu Miwa, Masayoshi Yoshii, Takeshi Horio, Akira Okayama, Hitonobu Tomoike, Yuhei Kawano, Toshiyuki Miyata.   

Abstract

OBJECTIVES: Mice deficient in the regulator of G-protein signaling 2 (RGS2) exhibit a strong hypertensive phenotype. We studied whether genetic variations in RGS2 are implicated in hypertension or other phenotypes in Japanese hypertensive individuals and the general population.
METHODS: We sequenced all exons of RGS2 and the promoter region in 953 and 48 hypertensive individuals, respectively. Genotyping by the TaqMan polymerase chain reaction method was performed for six missense or frameshift mutations and common single nucleotide polymorphisms in the general population, with a sample size of 1872 individuals (862 men and 1011 women).
RESULTS: We identified five novel missense mutations (Q2L; n = 2, Q2R; n = 1, M5V; n = 1, R44H; n = 2, Q78H; n = 1) and one novel frameshift mutation (1925-1926insT; n = 2) in a heterozygous state, in addition to 33 variations including five common single nucleotide polymorphisms. Six missense/frameshift mutations and three common single nucleotide polymorphisms (-638A > G, 1026T > A, 1891-1892delTC) were successfully genotyped in the general population. Mutations Q2L (n = 2), M5V (n = 1), and 1925-1926insT (n = 2) were only identified in hypertensive subjects. Six out of seven individuals with the R44H mutation, which occurs in the amphipathic alpha-helical domain of RGS2, had hypertension. The results showed a significant association of two common single nucleotide polymorphisms, 1026T > A [TT versus TA + AA: odds ratio (OR) 1.33; 95% confidence interval (CI) 1.02-1.74; P = 0.035] and 1891-1892delTC (I: insertion allele, D: deletion allele, II versus ID + DD: OR 1.47; 95% CI 1.09-1.97; P = 0.012), with hypertension in women by multivariate logistic regression analysis.
CONCLUSION: Our results suggest that genetic variations in RGS2 contribute partly to the hypertensive phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16003176     DOI: 10.1097/01.hjh.0000174606.41651.ae

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  37 in total

1.  Regulator of G-protein signaling 2 repression exacerbates airway hyper-responsiveness and remodeling in asthma.

Authors:  Haihong Jiang; Yan Xie; Peter W Abel; Dennis W Wolff; Myron L Toews; Reynold A Panettieri; Thomas B Casale; Yaping Tu
Journal:  Am J Respir Cell Mol Biol       Date:  2015-07       Impact factor: 6.914

Review 2.  A finer tuning of G-protein signaling through regulated control of RGS proteins.

Authors:  Jacob Kach; Nan Sethakorn; Nickolai O Dulin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-27       Impact factor: 4.733

Review 3.  Genetic associations with hypertension: meta-analyses of six candidate genetic variants.

Authors:  Cheng Zhang; Lingyan Wang; Qi Liao; Lina Zhang; Leiting Xu; Cheng Chen; Huadan Ye; Xuting Xu; Meng Ye; Shiwei Duan
Journal:  Genet Test Mol Biomarkers       Date:  2013-07-16

Review 4.  Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets.

Authors:  Adam J Kimple; Dustin E Bosch; Patrick M Giguère; David P Siderovski
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

Review 5.  Physiological functions and clinical implications of the N-end rule pathway.

Authors:  Yujiao Liu; Chao Liu; Wen Dong; Wei Li
Journal:  Front Med       Date:  2016-09-07       Impact factor: 4.592

6.  Identification of a cAMP-response element in the regulator of G-protein signaling-2 (RGS2) promoter as a key cis-regulatory element for RGS2 transcriptional regulation by angiotensin II in cultured vascular smooth muscles.

Authors:  Zhongwen Xie; Dexiang Liu; Shu Liu; Lindsay Calderon; Guogang Zhao; John Turk; Zhenheng Guo
Journal:  J Biol Chem       Date:  2011-11-04       Impact factor: 5.157

Review 7.  Pharmacological Modulation of the N-End Rule Pathway and Its Therapeutic Implications.

Authors:  Jung Hoon Lee; Yanxialei Jiang; Yong Tae Kwon; Min Jae Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-01       Impact factor: 14.819

8.  Control of mammalian G protein signaling by N-terminal acetylation and the N-end rule pathway.

Authors:  Sang-Eun Park; Jeong-Mok Kim; Ok-Hee Seok; Hanna Cho; Brandon Wadas; Seon-Young Kim; Alexander Varshavsky; Cheol-Sang Hwang
Journal:  Science       Date:  2015-03-13       Impact factor: 47.728

9.  Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent.

Authors:  Nicole K Littlejohn; Rick B Siel; Pimonrat Ketsawatsomkron; Christopher J Pelham; Nicole A Pearson; Aline M Hilzendeger; Beth A Buehrer; Benjamin J Weidemann; Huiping Li; Deborah R Davis; Anthony P Thompson; Xuebo Liu; Martin D Cassell; Curt D Sigmund; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-27       Impact factor: 3.619

10.  Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study.

Authors:  Ken Sugimoto; Tomohiro Katsuya; Kei Kamide; Tomomi Fujisawa; Izumi Shimaoka; Mitsuru Ohishi; Ryuichi Morishita; Toshio Ogihara; Hiromi Rakugi
Journal:  Int J Hypertens       Date:  2010-08-24       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.